IBT full logo

 

Infant Bacterial Therapeutics AB (“IBT”) is a pharmaceutical company based in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of Lactobacillus reuteri, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis (“NEC”), a fatal, rare disease that afflicts premature infants. IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

 

Read more about NEC here
Read more about IBP-9414 DEVELOPMENT PROGRAM here

Read more about IBP-1016 DEVELOPMENT PROGRAM and gastroschisis here

 

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser.